ArticleFrontiers in genetics2026
Network-based analysis identifies shared mechanisms between ischemic stroke and myocardial infarction and therapeutic ingredients of Buyang Huanwu Decoction.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ischemic stroke (IS) and myocardial infarction (MI) share overlapping etiology and pathology, highlighting the need for dual-effective therapies. Buyang Huanwu Decoction (BHD) has shown efficacy against both diseases individually, but its core ingredients and dual therapeutic mechanisms remain unclear. Methods: Using network-based analysis, we identified shared targets and convergent pathways for IS and MI, prioritized BHD ingredients by network proximity, and performed functional enrichment analyses. Molecular docking validated interactions between the key target GSK-3β and core ingredients, and surface plasmon resonance (SPR) experimentally determined the binding affinity of the top-ranked ingredient, Myricanone, to GSK-3β. Results: Thirteen shared core targets were identified, with the "Lipid and atherosclerosis" pathway as the principal common mechanism. Ten key BHD ingredients with predicted dual therapeutic effects were prioritized. Among the shared targets, Conclusion: These findings elucidate the shared mechanisms of BHD against IS and MI, supporting its potential as a multi-target phytotherapeutic strategy for ischemic cardio-cerebrovascular disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.